SEPI-IA

The SEPIA-IA (Simulación Evolutiva Pulmonar Intersticial con Inteligencia Artificial, or Evolutionary Simulation of Interstitial Lung Disease with Artificial Intelligence) project aims to improve the diagnosis of interstitial lung diseases through the use of cutting-edge artificial intelligence techniques applied to medical imaging.

The prototype developed can analyze lung images - such as X-rays or CAT scans - to identify lesions that may go unnoticed in routine clinical practice. Thanks to the application of AI algorithms, the solution is able to detect subtle patterns not visible to the human eye, facilitating earlier identification of these conditions and contributing to greater diagnostic and therapeutic accuracy.

GMV, a multinational company specializing in technological innovation solutions, and Tecnalia, a European applied research center, were involved in the technological development of the prototype. Specialists from Bellvitge University Hospital also contributed their clinical expertise, allowing the tool to be validated in a real-world healthcare setting and aligned with healthcare needs.

SEPIA-IA’s capabilities include the automatic generation of clinical reports based on image analysis, optimizing evaluation times and facilitating decision making by healthcare professionals.

On 23 March 2026, a ceremony presided over by the Spanish minister of Science, Innovation and Universities, Diana Morant, officially transferred a prototype to Bellvitge University Hospital in an effort to improve the diagnosis of rare lung diseases.

This project reflects the potential of artificial intelligence to transform medical diagnostics, improving early detection and contributing to more accurate and personalized healthcare.